A Clinical Study to Identify Centrally Related Factors Between the Innate Immune and Autoimmune System in SLE - A Clinical Study to Identify Centrally Related Factors Between the Innate Immune and Autoimmune System in SLE

niversity of Occupational and Environmental Health, Japan0 个研究点目标入组 50 人开始时间: 2020年10月7日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1. Patient who has a history of receiving any of following treatments for a predetermined period prior to the baseline examination. -Steroid pulse therapy (within 1 month) -Oral formulation of immunosuppressants (within 3 months) Cyclophosphamide, cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, mycophenolate mofetil, methotrexate, mizoribine -Intravenous administration of immunosuppressants (within 6 months) -Biological product (within 12 months) Belimumab -Other unapproved treatments for SLE (within 12 months) Rituximab, study drug, etc. for SLE -Cytapheresis (within 12 months) 2.Patient diagnosed with collagen disease other than SLE and who has experienced the therapeutic intervention (including non-drug treatment) in the past. 3.Patient who is positive in any of following viral tests at screening period or within 3 months prior to baseline (including the period prior to consent for this study). -Human immunodeficiency virus (HIV) -Hepatitis B surface antigen (HBs antigen) -Hepatitis B surface antibody (HBs antibody) However, if it is clearly due to hepatitis B vaccination, and HBs antibody alone is positive and hepatitis B virus DNA (HBV-DNA) assay is negative, participation is allowed. -Hepatitis B virus core antibody (HBc antibody) -Hepatitis C virus antibody (HCV antibody) -Human T-cell leukemia virus type-1 antibody (HTLV-1 antibody) 4.Other patients considered as not appropriate for participation of the study by investigator (or subinvestigator).

发起方

niversity of Occupational and Environmental Health, Japan